# A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)

> **NCT07709000** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 60 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukaemia
- Small Lymphocytic Lymphoma
- Hematologic Malignancies

## Interventions

- **BIOLOGICAL:** MK-1045
- **DRUG:** Acetaminophen (or similar antipyretic)
- **DRUG:** Diphenhydramine (or similar antihistamine)
- **DRUG:** Dexamethasone
- **BIOLOGICAL:** Tocilizumab
- **BIOLOGICAL:** Tocilizumab biosimilar
- **BIOLOGICAL:** Siltuximab

## Key facts

- **NCT ID:** NCT07709000
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-09
- **Primary completion:** 2033-11-16
- **Final completion:** 2033-11-16
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07709000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07709000, "A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07709000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*